GLP-1 receptor agonists × glycemic control

TrialDiabetes care2024

Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.

Steven E Kahn et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 17,604 people · 2024

Not counted

Lowered glycemic control

−0.32percentage points−0.33 to −0.30

As reported

difference −0.32 percentage points, 95% CI −0.33 to −0.30

One number in the abstract

the abstract, start to end

in both arms, with a mean difference of -0.32 percentage points (95% CI -0.33

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.32−0.33 to −0.30
GLP-1 receptor agonistsGlycemic control
1 / 3

44 papers cite it

2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 38907683